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Cancer as a mitochondrial metabolic
disease
Thomas N. Seyfried*
Biology Department, Boston College, Chestnut Hill, MA, USA
Cancer is widely considered a genetic disease involving nuclear mutations in oncogenes
and tumor suppressor genes. This view persists despite the numerous inconsistencies
associated with the somatic mutation theory. In contrast to the somatic mutation theory,
emerging evidence suggests that cancer is a mitochondrial metabolic disease, according
to the original theory of Otto Warburg. The findings are reviewed from nuclear cytoplasm
transfer experiments that relate to the origin of cancer. The evidence from these
experiments is difficult to reconcile with the somatic mutation theory, but is consistent
with the notion that cancer is primarily a mitochondrial metabolic disease.
Keywords: Warburg effect, fermentation, oxidative phosphorylation, mitochondria, microenvironment, cybrids,
tumorigenesis, carcinogenesis
Introduction
The prevailing view today is that cancer is a genetic disease involving nuclear mutations in
oncogenes and tumor suppressor genes (Hanahan andWeinberg, 2011). A typical tumor is thought
to contain two to eight so-called “driver gene” mutations that regulate the tumorigenic phenotype
(Vogelstein et al., 2013; Hou and Ma, 2014). The nuclear genomic instability seen in nearly
all types of tumor cells is considered the primary cause of the cancer’s hallmarks that include
sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative
immortality, enhanced angiogenesis, and activation of invasion and metastasis (Hanahan and
Weinberg, 2011). The somatic mutations thought to be the origin of cancer arise randomly
during DNA replication in normal noncancerous stem cells (Tomasetti and Vogelstein, 2015). The
somatic mutation theory reigns as the most widely accepted view of the origin of cancer and is
the justification for developing personalized genetic therapies for managing the various forms of
the disease (Vaux, 2011; McLeod, 2013; Hou and Ma, 2014). Despite numerous inconsistencies
associated with the somatic mutation theory (Rous, 1959; Sonnenschein and Soto, 2000; Soto and
Sonnenschein, 2004; Baker and Kramer, 2007; Burgio and Migliore, 2015), the theory is presented
as if it were dogma inmost current college textbooks of genetics, biochemistry, and cell biology, and
is the mainstay of the National Cancer Institute in stating that, “Cancer is a genetic disease—that is,
it is caused by changes to genes that control the way our cells function, especially how they grow and
divide” (http://www.cancer.gov/cancertopics/what-is-cancer).
As an alternative to the somatic mutation theory, emerging evidence suggests that cancer is
primarily a mitochondrial metabolic disease (Seyfried and Shelton, 2010; Hu et al., 2012; Verschoor
et al., 2013; Seyfried et al., 2014). The view of cancer as a metabolic disease originated with the
experiments of Otto Warburg (Warburg, 1956a,b; Burk et al., 1967). Respiratory insufficiency is
the origin of cancer according to Warburg’s theory. All other phenotypes of the disease, including
the somatic mutations, arise either directly or indirectly from insufficient respiration (Warburg,
1956a; Seyfried, 2012a; Seyfried et al., 2014). Warburg’s metabolic theory was also in line with the
concepts of C. D. Darlington and others showing that cancer is largely a cytoplasmic mitochondrial
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disease (Woods and Du Buy, 1945; Darlington, 1948).
Proponents of the somatic mutation theory, however, consider
the abnormal energy metabolism of tumor cells as simply
another phenotype that “is programmed by proliferation-inducing
oncogenes and defective tumor suppressor genes” (Hanahan and
Weinberg, 2011). In light of the overwhelming acceptance of the
somatic mutation theory, it would be good to reconsider data
from the nuclear transfer experiments that are inconsistent with
the somatic mutation theory.
The rationale for the nuclear transfer experiments is to
determine whether the genome of somatic cells can direct normal
development (Gurdon and Wilmut, 2011). These same types
of experiments can also be used to test the somatic mutation
theory of cancer. If nuclear somatic mutations are the origin of
cancer cells, then the hallmark cancer phenotype, dysregulated
cell proliferation, should occur following the transfer of a tumor
nucleus into a normal cell cytoplasm. In other words, the
somatic mutations in the tumor cell nucleus should determine
the tumorigenic phenotype of abnormal cell growth. On the
other hand, if mitochondrial dysfunction is the origin of cancer
cells, then the tumorigenic phenotype should follow the type
of mitochondria in the cell. In other words, mitochondria
from non-cancerous cells should suppress tumorigenesis whereas
mitochondria of tumor cells should enhance tumorigenesis
regardless of whether the nucleus present is from a normal cell
or from a tumor cell. It would therefore be important to consider
the findings from the nuclear-cytoplasm transfer studies, as I
previously described (Seyfried, 2012d).
Normal Cytoplasm Suppresses
Tumorigenesis in Cell Cybrids
Suppression of tumorigenicity was observed when the cytoplasm
of enucleated normal cells was fused with nucleated tumor cells to
form cybrids (Seyfried, 2012d). Cybrids contain a single nucleus
with a mixture of cytoplasm from two different cells. To examine
the influence of cytoplasm on the expression of tumorigenicity
in cybrids, Koura fused intact B16 mouse melanoma cancer
cells with cytoplasts (absent nucleus) from non-tumorigenic
rat myoblasts (Koura et al., 1982). The reconstituted cybrids
exhibited a unique morphology and cellular arrangements
different from that of the parental cells. Tumorigenicity was
reduced in all the reconstituted clones and cybrids soon after
their isolation, but tumorigenicity re-appeared in some clones
after extended cultivation of the cells in vitro (Koura et al.,
1982; Seyfried, 2012d). The effects of the unnatural cell culture
environment on mitochondrial respiration could account in
part for the reversion to tumorigenicity seen in some clones
(Warburg, 1956a; Kiebish et al., 2009). The Koura et al findings
showed that normal cytoplasm, containing mitochondria from
non-tumorigenic cells, could suppress the malignant phenotype
of tumor cells (Seyfried, 2012d). Although these observations
were not linked to Warburg’s theory, the findings question the
dominant role of the nucleus in the origin of tumorigenesis.
In a more comprehensive series of experiments, Israel,
and Schaeffer demonstrated that suppression of malignancy
could reach 100% in cybrids containing tumorigenic nuclei
and normal cytoplasm (Israel and Schaeffer, 1987). On the
other hand, tumors formed in 97% of mice implanted with
cybrid cells derived by fusion of cytoplasts from malignant cells
(nucleus absent) with karyoplasts from normal cells (nucleus
present). The important feature of their study was that the non-
transformed and the transformed cells were all derived from
an original cloned progenitor cell with a common nuclear and
cytoplasmic background (Israel and Schaeffer, 1988; Seyfried,
2012d). These findings showed that normal cell nuclei could not
suppress tumorigenesis when placed in tumor cell cytoplasm.
In other words, normal nuclear gene expression, which would
presumably include tumor suppressor genes, was unable to
suppress malignancy. An alternative view is that the cytoplasm
of the tumor cell could reprogram the nucleus to become
tumorigenic. These findings are consistent with the view of
Darlington who showed that it was the cytoplasm, rather than
the nucleus, that determined the tumorigenic state of the cells
(Darlington, 1948). Israel and Schaeffer did not identify the
molecular basis for the cytoplasmic control of tumorigenesis,
but they did suggest that epigenetic changes in nuclear gene
expression might be responsible for the phenomenon (Seyfried,
2012d).
It is obvious that the findings of Israel and Schaeffer
are inconsistent with the somatic mutation theory, but their
observations would support the concepts of Warburg’s theory.
These investigators, however, did not connect their observations
to Warburg’s theory. Instead they linked their observations
to a potential epigenetic phenomenon (Israel and Schaeffer,
1988). It is important to recognize that mitochondria are
a powerful extra nuclear epigenetic system that can control
nuclear gene expression through the retrograde signaling system
(Minocherhomji et al., 2012; Seyfried, 2012e). A personal account
of the Israel and Schaeffer studies in light of the competing
theories of cancer has appeared (Christofferson, 2014).
The findings of Israel and Schaeffer that normal cytoplasm
could suppress tumorigenicity were also consistent with the
observations of Shay and Werbin (Shay and Werbin, 1988; Shay
et al., 1988; Seyfried, 2012d). Shay and Werbin identified several
factors that could influence the outcome of cybrid experiments
designed to uncover cytoplasmic suppressors of tumorigenicity.
These influencing factors included, (1) the relative amounts
of non-tumorigenic and tumorigenic cytoplasm in cybrids; (2)
the time interval that cybrids are passaged in culture prior to
testing their tumorigenicity; (3) whether or not mutagenesis with
carcinogens were used to introduce genetic markers in the cells;
and (4) the type of cell combinations that were used. It would
not therefore be surprising that varied results could occur with
the cybrid experiments if the confounding variables were not
controlled. In general, however, the observations of Shay and
Werbin were consistent with the conclusion of the Israel and
Schaeffer experiments. Although Shay and Werbin mentioned a
possible role for mitochondria in the suppressive effects of the
cytoplasm on tumorigenesis, they also did not consider their
results in light of Warburg’s metabolic theory (Seyfried, 2012d).
Howell and Sager, however, were aware of the relationship of
Warburg’s theory and the findings from the various cybrid studies
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(Howell and Sager, 1978; Seyfried, 2012d). These investigators
speculated that the results from the cybrid experiments could
help distinguish whether it was the cytoplasm or the nucleus
or that determined tumorigenicity. They showed that cytoplasm
of non-tumorigenic normal cells suppressed the rate and extent
of tumor formation in nude mice when fused with nucleated
tumorigenic counterparts (Seyfried, 2012d). Howell and Sager
stated; “if tumor cell mitochondria are defective, as Warburg
postulated, then suppression could result from the introduction of
mitochondria from normal cells into cybrids” (Howell and Sager,
1978). These findings like those of Koura, Israel and Schaeffer,
and Shay and Werbin supported Warburg’s theory and are
difficult to explain with the somatic mutation theory (Seyfried,
2012d).
To further evaluate the role of the cytoplasm and the nucleus
in the control of malignancy, Jonasson and Harris conducted
several interesting studies in human/mouse hybrids. These
investigators evaluated in vivo tumor malignancy in a range
of hybrid clones derived from fusions of a malignant mouse
melanoma with diploid human fibroblasts and lymphocytes
(Jonasson and Harris, 1977). They observed that the human
diploid cells were as effective as the mouse diploid cells in
suppressing themalignancy of themousemelanoma cells, despite
the preferential elimination of the human chromosomes in the
hybrid clones. Malignancy was also suppressed in a hybrid clone
where only a single human X chromosome was present. Jonasson
and Harris showed that this clone continued to produce few
tumors, even after they used back selection to remove this
remaining X chromosome. These findings suggested that no
human nuclear genetic material was responsible for suppression
of malignancy. These findings would rule out a nuclear
epigenetic explanation for suppression of tumorigenesis, but
would not exclude an extra-nuclear (mitochondrial) epigenetic
explanation.
Jonasson and Harris also constructed hybrids between the
melanoma cells and human fibroblasts that were irradiated
before cell fusion (Jonasson and Harris, 1977). They showed
that the incidence of tumor take in nude mice was greater in
crosses between the mouse melanoma cells and the irradiated
human fibroblasts than in crosses between the melanoma cells
and the un-irradiated human fibroblasts (Jonasson and Harris,
1977). These investigators concluded that the suppression of
malignancy involved the participation of a radio-sensitive extra-
chromosomal element. The findings from the Jonasson and
Harris studies were interesting for several reasons (Seyfried,
2012d). First, their observations were consistent with those of
several other cybrid studies suggesting that factors in normal
cytoplasm could suppress tumorigenicity. Second, no human
nuclear genetic material was responsible for the suppressive
effect. Lastly, high-dose gamma radiation could destroy the
cytoplasmic factor that was responsible for tumor suppression.
This last observation was consistent with the findings of
both Warburg and Darlington in showing that high-dose
radiation destroys mitochondrial respiration and the cytoplasmic
plasmagene, which has multiple characteristics of mitochondria
(Darlington, 1948; Warburg, 1956a). Low dose radiation can
cause nuclear mutations but not cancer, whereas high dose
radiation damages both the nucleus and mitochondria and can
cause cancer.
It is interesting that Jonasson and Harris excluded the
mitochondria in preference to a centrosome origin for the
suppression effect of cytoplasm on tumorigenesis (Jonasson and
Harris, 1977). Their opinion was based largely on the findings
of other investigators showing that no human mitochondrial
DNA or proteins were detected in the human-mouse cybrids.
More recent studies in transmissible cancers, however, show that
tumor mitochondria can integrate with normal mitochondria
in some tumors (Rebbeck et al., 2011). I suggested that this
integration might reduce or partially correct the respiratory
insufficiency in the tumor cell mitochondria thus suppressing
tumorigenicity (Seyfried, 2012d). The work of King and Attardi
also support this possibility in showing that exogenous mtDNA
could enhance respiration in cells lacking functional mtDNA
(King and Attardi, 1988, 1989). The more recent findings of Tan
et al. also support the possibility in showing that mtDNA can
be transferred horizontally from host cells to tumor cells in the
microenvironment (Tan et al., 2015). Viewed collectively, these
observations are in general agreement with Warburg’s original
theory.
It is not possible, however, to exclude all influence of the
nuclear genome in the suppression of tumorigenicity. Saxon and
co-workers showed that the microcell transfer of Chromosome
11 suppressed tumorigenicity in HeLa cells (Saxon et al., 1986).
They suggested that a tumor suppressor gene could be present
on Chromosome 11. These findings also suggest an interaction
between Chromosome 11 and mitochondria (Seyfried, 2012d).
Is it possible that a gene on Chromosome 11 facilitates
mitochondrial respiration thus suppressing tumorigenicity in the
HeLa cells? (Seyfried, 2012d). It is also interesting that defects
on Chromosome 11 have been associated with the Wilms kidney
tumor and with childhood neuroblastoma. Further studies will
be needed to determine if tumorigenic suppression involves
interactions between mitochondrial respiration and genes on
Chromosome 11.
Evidence from rho0 Cells Supporting a
Mitochondrial Origin of Tumorigenesis
Singh and co-workers showed that the exogenous transfer of
wild type mitochondria to cells with depleted mitochondria DNA
(rho0 cells) could reverse the altered expression of the APE1DNA
repair protein and the tumorigenic phenotype, thus providing
evidence for the role of mitochondria in the suppression of
tumorigenicity (Singh et al., 2005). Mitochondrial respiration
appears responsible for the efficiency of APE1-mediated DNA
repair. The rho0 cells have impaired respiration due to the lack
mtDNA that is essential for normal cellular respiration. It is
my view that transfer of normal mtDNA to the rho0 cells will
restore respiration, turn off the mitochondria/nuclear retrograde
response, and prevent nuclear genomic instability (Seyfried,
2012d). These findings suggest that it is efficient mitochondrial
respiration that prevents cancer. The more recent studies of
Cruz-Bermudez support these observations (Cruz-Bermúdez
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et al., 2015). I also described how mitochondrial enhancement
therapies could prevent cancer (Seyfried, 2012b).
Wallace, and colleagues also provided support for the
importance of respiration in the origin of prostate cancer
(Petros et al., 2005). These investigators introduced the T8993G
pathogenic mtDNA mutation into PC3 prostate cancer cells
through cybrid transfer to determine whether the mutant
pancreatic tumors expressed increased ROS levels and growth
rate. The engineered PC3 prostate cancer cells were then tested
for tumor growth in nude mice. The resulting mutant T8993G
cybrids produced tumors that were seven-times larger than those
produced from the wild-type cybrids. In contrast to the rapid
growth of the mutant cybrids, the wild-type cybrids grew very
slowly in the mice. Significantly more ROS were also produced
in the tumors derived from T8993G mutant cybrids than tumors
without this mutation. The carcinogenic and mutagenic action
of ROS will damage respiration and produce nuclear genomic
instability (Waris and Ahsan, 2006; Klaunig et al., 2010; Seoane
et al., 2011). Additional experiments from the Wallace group
and more recently from Cruz-Bermudez and co-workers showed
that introduction of mtDNA mutations could reverse the anti-
tumorigenic effect of normal mitochondria in cybrids (Petros
et al., 2005; Cruz-Bermúdez et al., 2015). These findings indicate
that some mtDNA mutations can play an important role in the
etiology of cancer and that cancer can be best defined as a type
of mitochondrial metabolic disease. These findings are also more
in line with Warburg’s theory than with the somatic mutation
theory.
Normal Cytoplasm Suppresses
Tumorigenesis In Vivo: The Lucke Frog
Renal Tumor
Substantial information exists showing that the nuclei of tumor
cells can be reprogrammed to form normal tissues when they
are transplanted into normal cytoplasm, despite the continued
presence of the tumor-associated genomic defects in the cells
of the derived tissues (Seyfried, 2012d). McKinnell, Deggins,
and Labat showed that cell nuclei from frog renal tumors
could direct normal frog development following transplantation
of the renal tumor cell nucleus into an enucleated normal
egg cell (McKinnell et al., 1969). The experiments involved
implantation of nuclei, isolated from Lucke frog renal cell
tumors, into fertilized enucleated eggs from normal diploid
frogs. Importantly, the cells of the renal tumor were triploid in
containing three copies of all chromosomes. Triploid tadpoles
developed normally from the triploid tumor cell nuclei, and
revealed functional tissues of many types. This experimental
strategy made it possible to distinguish development initiated
by the transplanted nucleus from development influenced by
an inadvertently retained maternal diploid nucleus (McKinnell
et al., 1969). “The investigators showed that ciliated epithelium
propelled the tadpoles in the culture dishes. The tadpoles swam
when stimulated. The tadpoles had functional receptors, nerve
tissue, and striatedmuscle necessary for swimming. Cardiac muscle
pumped blood cells through the gills. Suckers secreted abundant
mucus. Clearly seen were a pronephric ridge, eye anlage, nasal pit,
and open mouth, as was the differentiation of the head, body, and
the tail. The tail fin regenerated after being clipped for chromosome
study. Moreover, sections of embryos developed from transplanted
triploid tumor nuclei revealed apparent normal development of the
brain, spinal cord, optic cup with lens, auditory vesicle, somites,
pronephric tubules, pharynx, midgut, and notochord. No evidence
of abnormal cell growth was seen in any of the organs or tissues
examined” (Seyfried, 2012d). These findings showed that nuclei
derived from tumor cells could direct normal developmental and
did not induce dysregulated cell growth, the signature phenotype
of tumorigenesis. It is interesting that the tadpoles containing
tumor nuclei could not complete development to normal adult
frogs. It remains unclear if the tumor-associated nuclear defects
were responsible for preventing late stage development of the
frogs.
The findings from the Lucke frog experiments are consistent
with the mitochondrial metabolic theory, but are difficult to
reconcile with the somatic mutation theory of cancer (Seyfried,
2012d). The enucleated egg would contain the mitochondria
from the normal egg cytoplasm. These mitochondria would
direct normal energy homeostasis during development. It is my
view that normal energy homeostasis “suppresses tumorigenesis
despite the presence of the tumor nucleus and somatic mutations”
(Seyfried, 2012d). Later studies suggested that loss of the Lucke
tumor herpes virus was linked to the loss of tumorigenicity
(Carlson et al., 1994). This virus was considered the etiological
agent responsible for the origin of the renal tumors. It is now
known, however, that the herpes virus can alter mitochondrial
function to induce tumorigenesis (D’agostino et al., 2005;
Seyfried, 2012c). Indeed, Ackerman and Kurtz showed that
herpes viruses have an intimate attachment to mitochondria
that causes dysfunctional respiration (Ackermann and Kurtz,
1952). Hence, the replacement of virus-damaged mitochondria
with normal mitochondria from the host could the suppress
tumorigenesis despite the presence of the renal tumor nucleus
(Seyfried, 2012d). The findings from the frog renal tumor are
similar to those described above from the cell cybrid experiments,
and cast doubt on the somatic mutation theory as an explanation
for this type of cancer.
Normal Cytoplasm can Suppresses
Tumorigenic Phenotypes in Mice
Findings similar to those obtained with the Lucke frog renal
tumor were also obtained following nuclear transfer in mouse
tumors. Morgan and colleagues showed that nuclei from
a mouse brain tumor, arising from cerebellar granule cells
(medulloblastoma), could direct normal development when the
tumor nuclei were transplanted into enucleated somatic cells
(Li et al., 2003). Figure 1 from their study shows that normal
embryonic tissues and germ cell layers can be formed from cells
containing the tumor nuclei. These investigators showed that
the transfer of the tumor cell nucleus into normal cytoplasm
suppressed the tumorigenic phenotype despite the continued
presence of the mutant nuclear gene (Patched) that was thought
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FIGURE 1 | Nuclei from brain tumors support normal mouse embryonic
development. (A) H&E staining of a mouse embryo (embryonic day, E-7.5)
derived from a cell containing the transplanted “nucleus” from a
medulloblastoma tumor. (B) the boxed area in (A) (at a higher magnification)
showing the three germ layers; ecto-placental cone (pla); embryonic
endoderm (end); embryonic mesoderm (mes,); embryonic ectoderm (ect),
Scale bar, 20µm. The cytoplasm will contain normal mitochondria. The results
show that a nucleus derived from a brain tumor can direct normal embryonic
development when implanted into normal cytoplasm. Reprinted with
permission from Li et al. (2003).
responsible for the original tumorigenic phenotype (Li et al.,
2003; Seyfried, 2012d). The transplanted medulloblastoma nuclei
produced post-implantation embryos that underwent normal
tissue differentiation and early stage organogenesis. Importantly,
no malignancies or abnormal cell growth were seen in any of
the recipient mice. Normal proliferation control was observed
in cultured blastocysts indicating that nuclear somatic mutations
alone were not likely responsible for the original tumorigenic
phenotype (Li et al., 2003).
Li and co-workers suggested that the tumorigenic Patched
mutation causing medulloblastoma must act within the context
of the cerebellar granule cell lineage, and that the mutation
did not support the malignant cell proliferation outside
the cerebellum (Li et al., 2003). Although an epigenetic
reprogramming of the medulloblastoma nuclei was offered as an
explanation for their observations, it is also possible that their
observations resulted from the replacement of dysfunctional
mitochondria with normally functional mitochondria that would
be present in the recipient stem cell (Seyfried, 2012d). The results
in thismouse brain tumormodel are consistent with those seen in
the Lucke frog renal tumor. The findings from Li et al would also
support the earlier observations of Mintz and Illmensee showing
that normal appearing mice could be cloned from tumor cell
nuclei obtained from malignant teratomas, and that “structural
mutations in the nuclear genome could not be responsible for
tumor formation” (Mintz and Illmensee, 1975). Considered
collectively, these findings indicate that nuclear gene mutations
alone cannot account for the origin of tumors. Although
the observations reveal the potential role of mitochondria in
modulating tumorigenesis, they are difficult to explain under the
somatic mutation theory.
The work of Hochedlinger, Jaenisch, and colleagues also
supported the findings from the Lucke frog and the mouse
medulloblastoma experiments (Hochedlinger et al., 2004). These
investigators found that the nuclei of mouse melanoma cells
could produce normal-appearing blastocysts without signs of
dysregulated cell proliferation. They also showed that normal
blastocysts could be formed from p53 -/- breast cancer cells,
and that normal blastocysts and embryonic cell lines could
be formed from melanoma nuclei. Figure 2 shows an image
from their study of mouse embryo cloned from the nucleus
of a melanoma. These investigators suggested that the oocyte
environment could suppress the malignant phenotype of the
various tumor types, and that tumor nuclei could direct normal
appearing development in early mouse embryos (Hochedlinger
et al., 2004; Seyfried, 2012d). The oocyte cytoplasm would
be expected to contain normal mitochondria. Based on the
previously mentioned studies in cybrids, frogs, and mice, it
would be reasonable to assume that the respiratory competent
normal mitochondria would suppress tumorigenicity. It can be
suggested that tumor nuclei would direct normal development as
long as normal functioning mitochondria exist in the cytoplasm.
However, the authors showed that tumors could form in
some mice cloned from tumor nuclei, as long as the Ras
oncogene was expressed together with the tumor-associated
mutations. It is now known that the Ras oncogene induces
tumorigenesis through an inhibitory effect on mitochondrial
oxidative phosphorylation (Hu et al., 2012). Hence, respiratory
damage is an essential requirement for tumorigenesis.
The studies from the Hochedlinger and Jaenisch group
also showed that embryonic stem cells, derived from cloned
melanoma cells, could differentiate into multiple somatic cell
lineages including fibroblasts, lymphocytes, and melanocytes
(Hochedlinger et al., 2004). “Remarkably, normal development
occurred despite the persistence of severe chromosomal changes
and mutations documented by array-comparative genome
hybridization (CHG)” (Hochedlinger et al., 2004; Seyfried,
2012d). The investigators concluded that secondary chromosomal
changes, associated with malignancy, do not necessarily interfere
with pre-implantation development, embryonic stem cell
derivation, and a broad nuclear differentiation potential
(Hochedlinger et al., 2004). These observations suggest that
nuclear gene mutations alone cannot account for the origin of
cancer and are therefore inconsistent with the somatic mutation
theory. Unfortunately, these investigators also did not discuss
their findings in relationship to mitochondrial function or to
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FIGURE 2 | Mouse embryo cloned from tumor cell nucleus. An E-9.5
mouse embryo cloned from a melanoma-derived R545-1 embryonic stem cell.
The embryo expressed neural tube closure, a beating heart, and normal limb
bud development consistent with regulated cell growth. The result shows that
the nucleus of a malignant melanoma can direct early mouse development
when placed into normal cytoplasm containing normal mitochondria. However,
irreversible genetic alterations, from the melanoma donor genome, disrupted
complete development similar to the situation found in Lucke frogs that were
cloned from nuclei of renal tumors (McKinnell et al., 1969). Reprinted from in
this figure (Hochedlinger et al., 2004) with permission.
the Warburg theory despite showing evidence in line with the
theory.
Suppressed Tumorigenicity in the Liver
Microenvironment
Grishman and co-workers reported that rat liver tumor cell
lines expressing aneuploidy formed aggressive tumors when
grown subcutaneously, but did not form tumors when grown
orthotopically in the liver (Coleman et al., 1993; Seyfried, 2012d).
The tumor cells became morphologically differentiated following
intrahepatic transplantation in adult syngeneic Fischer 344 rats.
The authors concluded that close cell contacts or factors in
the hepatic microenvironment suppressed tumorigenicity. It is
known that cell-cell fusions occur in murine liver (Faggioli
et al., 2008). Could it be possible that fusion between normal
hepatic cells and neoplastic hepatic cells, in the unique liver
microenvironment, might suppress tumorigenicity in a manner
similar to that seen in the cybrid experiments mentions above?
The recent findings from Tan and colleagues support the
horizontal transfer of mitochondrial DNA from host cells
to tumor cells (Tan et al., 2015). Further studies will be
needed to resolve issues of horizontal transfer of mitochondrial
components in the liver microenvironment.
The suppressive effect of normal mitochondria on
tumorigenesis links mitochondrial function to the long-standing
controversy on cellular differentiation and tumorigenicity
(Harris, 1988; Soto and Sonnenschein, 2004; Seyfried, 2012d;
Seyfried and Shelton, 2010). Respiration is required for the
emergence and maintenance of differentiation, while loss of
respiration leads to glycolysis, dedifferentiation, and unbridled
proliferation (Seyfried, 2012d). This observation is consistent
with the general hypothesis presented in this review, that
prolonged impairment of mitochondrial energy metabolism
underlies carcinogenesis (Warburg, 1969; Szent-Gyorgyi, 1977;
Seyfried, 2012d). This hypothesis would represent an epigenetic
origin of the disease in the classic sense (Nanney, 1958;
Holliday, 2006; Seyfried, 2012d). Replacement of dysfunctional
mitochondria with normal mitochondria will restore normal
energy homeostasis and the differentiated state.
Normal Mitochondria can Suppress
Tumorigenesis in Metastatic Breast Cancer
Recent studies from Kaipparettu, Wong, and colleagues show
that the introduction of non-cancerous mitochondria into
highly malignant breast cancer cells could reverse malignancy
and down regulate several oncogenic pathways, including
those involved with unregulated cell growth, viability under
hypoxia, anti-apoptotic properties, resistance to anti-cancer
drug, invasion, colony formation in soft agar, and in vivo tumor
growth in nude mice (Kaipparettu et al., 2013). Cybrids with
normal mitochondria showed enhanced mitochondrial function
including increased ATP synthesis, oxygen consumption and
respiratory chain activities despite the presence of the cancerous
nuclear genome. A remarkable finding was that even though
genes that encode most mitochondrial proteins are located in
the nucleus, introduction of mitochondria derived from the
non-cancerous cell to a cancer nuclear environment resulted
in suppression of oncogenic pathways and the tumorigenic
phenotype. Cruz-Bermudez et al recently reported similar
findings in showing that in vivo tumorigenicity was significantly
lower in cybrids containing the 143B osteosarcoma cell nucleus
and normal mitochondria than in 143B cells containing
mitochondria harboring various mutations in themtDNA (Cruz-
Bermúdez et al., 2015). In other words, normal mitochondria
could suppress tumorigenicity despite the continued presence
of the tumorigenic nucleus. The results from these studies
complement those from the above mentioned nuclear transfer
experiments and highlight the important role of mitochondria
in the origin and regulation of tumorigenesis. These findings
are in line with the view that tumorigenesis arises more from
mitochondrial defects than from somatic mutations in the
nuclear genome.
Inconsistencies and Difficulties
Any theory that attempts to explain a complex biological
phenomenon like cancer should address difficulties or
inconsistencies with the theory, rather than ignore them. I
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have attempted to address these issues. For example, Akimoto,
Hayashi, and co-workers reported that genome chimera mouse
fibroblasts carrying nuclear DNA from tumor cells and mtDNA
from normal cells expressed tumorigenicity, whereas those
carrying nuclear DNA from normal cells and mtDNA from
tumor cells did not (Akimoto et al., 2005). These observations
suggest that nuclear DNA, but not mtDNA, was responsible for
carcinogen-induced malignant transformation in these mouse
fibroblasts. These findings raise an issue regarding the role of the
nucleus and mitochondria in the origin of tumors and should be
considered in light of the in vivo nuclear transfer experiments
reported in this review. Israel and Schaeffer described the
role of diverse in vitro histories in contributing to some
inconsistencies seen in the cybrid studies (Israel and Schaeffer,
1988). Further studies will be needed to reconcile differences
in results obtained from some in vivo and in vitro transfer
experiments.
However, the role of mitochondrial DNA (mtDNA) in the
origin and progression of cancer is controversial. We were unable
to find any pathogenic mtDNA mutations in a broad range of
chemically induced and naturally arising mouse brain tumors
(Kiebish and Seyfried, 2005). Our studies were comprehensive
in that we sequenced the entire mitochondrial genome after
first isolating and purifying the mitochondria from the tumor
tissue. Many of the reported mtDNA mutations found in tumors
are thought to arise as artifacts possibly through amplification
of nuclear embedded mtDNA sequences (NUMTs) (Salas et al.,
2005; Schon et al., 2012). On the other hand, the tumorigenic
phenotype is associated with abnormal mitochondrial lipids
(Kiebish et al., 2008). Indeed, no tumor has yet been found with
a normal content or composition of cardiolipin, the signature
lipid of the inner mitochondrial membrane that regulates
oxidative phosphorylation (Kiebish et al., 2009; Claypool and
Koehler, 2012; Seyfried et al., 2014). Proteomic abnormalities
involving mitochondria have also been reported in various
tumors (Unwin et al., 2003; Ristow and Cuezva, 2009; Dai et al.,
2010; Deighton et al., 2014). These findings provide additional
evidence in support of Warburg’s original theory. Pedersen
documented the broad range of mitochondrial abnormalities that
are found in tumor cells (Pedersen, 1978). Hence, mitochondrial
abnormalities linked to cancer can involve more than just
mtDNA mutations. We recently summarized how most cancers
can arise from abnormalities in mitochondria structure and
function (Seyfried, 2012a; Seyfried et al., 2014).
If most cancers arise from chronic abnormalities in
mitochondrial respiratory capacity, why would cancer be rare in
some persons that inherit mutations damaging mitochondrial
function? For example, cancer is rare in patients with familial
amyotrophic lateral sclerosis (ALS) (Vigliani et al., 2000).
Familial ALS involves mutations in the Cu/Zn superoxide
dismutase gene (SOD), which disturbs respiratory function
and leads to neurodegeneration (Rosen, 1993; Dupuis et al.,
2004a,b). Tumors arising in neurons of the central nervous
system are rare, however, due to the inability of neurons to
sustain fermentation when respiration is compromised (Allen
et al., 2005). For example, mitochondrial ROS kills dopaminergic
neurons in Parkinson’s disease without producing cancer
(Eng et al., 2003). Cancer is also rare in children with Barth
syndrome that involves abnormalities in cardiolipin remodeling
and respiratory dysfunction (Claypool and Koehler, 2012;
Clarke et al., 2013). Children with Barth syndrome, however,
also express hypoglycemia, which would impede glucose
fermentation and the Warburg effect that would be needed
to drive tumorigenesis. Most tumors arise in cells that can
up-regulate the glycolytic pathway in order to compensate for
a gradual and chronic disruption in oxidative phosphorylation.
Cells that cannot make the energy transition from respiration
to fermentation will die and never become tumorigenic, as
Warburg first mentioned (Warburg, 1956a).
Multiple symmetric lipoma tumors with abnormal
mitochondria were found in carriers of the inherited
mitochondrial syndrome, myoclonus epilepsy and ragged-
red fibers (MERRF) (Holme et al., 1993). The lipomas
expressed mutations in the mtDNA gene encoding tRNA-
lysine indicating that the lipomas arose from the mtDNA
mutations. The mtDNA mutations were also linked to nuclear
genomic instability involving gross chromosomal abnormalities.
Although the tumors arose from the mtDNA mutation, the
nuclear genomic instability could have arisen as a secondary
consequence of the reported mitochondrial abnormalities. These
findings would be consistent with the view that the genomic
instability seen in tumors results as a secondary downstream
effect of mitochondrial dysfunction and altered oxidative
phosphorylation (Seyfried and Shelton, 2010; Chandra and
Singh, 2011; Seyfried et al., 2014; Bartesaghi et al., 2015). Recent
findings from Cruz-Burmedez et al show that tumorigenicity is
greater in association with mtDNA mutations that provoke less
severe mitochondrial dysfunction then with mtDNA mutations
that provoke severe dysfunction in oxidative phosphorylation
(Cruz-Bermúdez et al., 2015). These findings suggest that some
level of mitochondrial oxidative phosphorylation is required
for tumor initiation. However, oxidative phosphorylation is
not likely necessary for progression of highly malignant breast
tumors that have few if any mitochondria (Elliott et al., 2012). I
agree with the view of Eng and colleagues that further research
is needed into the genetic, cellular, and clinical aspects of
mitochondrial function in relationship to cancer risk (Eng et al.,
2003).
Summary of Nuclear-cytoplasmic Transfer
Experiments
Considered collectively, the findings reviewed here provide
compelling evidence showing that nuclear somatic mutations
alone cannot account for the origin of tumors, and that normal
cytoplasm containingmitochondria can suppress tumorigenicity.
It is interesting that the findings from the nuclear-cytoplasmic
transfer experiments are generally consistent across a broad range
of tumor types, animal species, and experimental techniques.
Several leaders in the field of genetics and developmental biology
conducted these studies (C. D. Darlington, H. Harris, B. Mintz,
R. Sager, J. Morgan, R. Jaenisch), which further supports the
validity of the findings. Moreover, most of the studies were not
done to test the somatic mutation theory of cancer, but rather
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were done to determine the importance of nuclear mutations
in directing the tumorigenic phenotype. Consequently, data
interpretation was largely unbiased. The general reproducibility
of the findings is notable in light of recent concerns regarding the
irreproducibility of important scientific results (McNutt, 2014).
Although numerous inconsistencies have been documented
that undermine the credibility of the somatic mutation theory
(Sonnenschein and Soto, 2008; Burgio and Migliore, 2015),
none of these are as powerful as those presented here from
the nuclear-cytoplasmic transfer experiments. Moreover, recent
studies from Chernet and Levin have shown that alterations in
bioelectric membrane signaling can produce metastatic behavior
of Xenopus melanocytes in the absence of somatic mutations
further suggesting that the tumorigenic phenotype is not
dependent on nuclear gene mutations (Chernet and Levin, 2014;
Chernet et al., 2014). In other words, nuclear mutations alone
are insufficient for producing tumors, whereas the tumorigenic
phenotype can be produced in some cells without nuclear
mutations. These findings seriously question the foundation of
the somatic mutation theory of cancer.
Although the nuclear-cytoplasmic transfer experiments fail
to support the somatic mutation theory, the data from these
experiments strongly support the Warburg theory of cancer.
Normal mitochondrial function reverses expression and the
Warburg effect because this effect is due to insufficient respiration
(Burk and Schade, 1956; Kaipparettu et al., 2013; Seyfried
et al., 2014). Aerobic fermentation is an effect of insufficient
respiration. Statements about a “reverse Warburg effect,” which
do not involve restored respiration in the tumor cells, are difficult
to reconcile in light of the information presented here (Pavlides
et al., 2009; Seyfried, 2012d). Normal mitochondria would
enhance respiration thus suppressing oncogene expression and
tumorigenicity, whereas mitochondria taken from cancer cells
cannot restore respiration or suppress tumorigenicity. According
to Warburg’s theory, it would be expected that the presence of
normal mitochondria in tumor cells would restore the cellular
redox state, down regulate the mitochondrial stress response,
and ultimately reduce or eliminate the need for fermentation
(the Warburg effect) to maintain viability (Seyfried et al., 2014).
In rephrasing, normal mitochondrial function maintains the
differentiated state thereby suppressing carcinogenesis, whereas
dysfunctional mitochondria can enhance cellular dedifferentiation
thereby facilitating carcinogenesis (Seyfried, 2012d). Cuezva
and Ristow also show that normal mitochondrial respiration
suppresses tumorigenesis (Ristow, 2006; Cuezva et al., 2009;
Ristow and Cuezva, 2009). Proliferation is the default state
of metazoan cells, i.e., the state under which cells are found
when they are freed from any active control (Sonnenschein and
Soto, 1999). Mitochondria can maintain the differentiated state
and quiescence. The loss of mitochondrial function will lead
eventually to the default state of unbridled proliferation, i.e.,
the metabolic phenotype that was present in all cells during
the anoxic alpha period of earth’s history (Szent-Gyorgyi, 1977;
Seyfried, 2012a). Figure 3 summarizes the role of mitochondria
in tumorigenesis.
The Origin of Cancer
It is well-known that reactive oxygen species (ROS) are produced
in defectivemitochondria largely through the coenzymeQ couple
(Veech, 2004). ROS are powerful mutagens of nuclear DNA and
can cause the genomic instability seen in most tumor cells (Waris
FIGURE 3 | Role of the nucleus and mitochondria in the origin of
tumors. Summary of a role of the mitochondria in the origin of
tumorigenesis, as we previously described (Seyfried, 2012d; Seyfried
et al., 2014). Normal cells are shown in green with nuclear and
mitochondrial morphology indicative of normal gene expression and
respiration, respectively. Tumor cells are shown in red with abnormal
nuclear and mitochondrial morphology indicative of genomic instability and
abnormal respiration, respectively. “(1) Normal cells beget normal cells. (2)
Tumor cells beget tumor cells. (3) Transfer of a tumor cell nucleus into a
normal cytoplasm begets normal cells, despite the presence of the
tumor-associated genomic abnormalities. (4) Transfer of a normal cell
nucleus into a tumor cell cytoplasm begets dead cells or tumor cells, but
not normal cells. The results suggest that nuclear genomic defects alone
cannot account for the origin of tumors, and that normal mitochondria
can suppress tumorigenesis” (Seyfried, 2012d). Original diagram from
Jeffrey Ling and Thomas N. Seyfried, with permission.
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and Ahsan, 2006; Seoane et al., 2011). Bartesaghi et al recently
showed that nuclear genomic instability, p53 inactivation, and
tumorigenic transformation occurred in neural progenitor cells
following damage to their oxidative phosphorylation (Bartesaghi
et al., 2015). It has been my view that the plethora of random
somatic mutations seen in tumors of almost every kind arise
ultimately as downstream effects of insufficient respiration
with compensatory fermentation (Seyfried and Shelton, 2010;
Seyfried, 2012a). Evidence is now accumulating in support for
this view (Waris and Ahsan, 2006; Seoane et al., 2011; Al
Mamun et al., 2012; Bartesaghi et al., 2015). Indeed, the gradual
transformation in cellular energy production from oxidative
phosphorylation to substrate level phosphorylation can account
not only for the collection of random mutations and genomic
instability seen in cancer cells, but can also account for all
of the disease hallmarks described by Hanahan and Weinberg
(Seyfried and Shelton, 2010; Hanahan and Weinberg, 2011;
Seyfried, 2012a). We also showed that the hallmark of metastasis
arises from damage to the respiration in cells of myeloid
origin or their fusion hybrids, which would naturally possess
the capability of surviving in the circulation and disseminating
throughout the body (Huysentruyt and Seyfried, 2010; Seyfried
and Huysentruyt, 2013). The data supporting the origin of cancer
as a mitochondrial metabolic disease should be compared with
the data supporting the “bad luck” origin of cancer through the
somatic mutation theory (Tomasetti and Vogelstein, 2015). It
should be obvious to most cancer biologists that the origin of
cancer as a type of mitochondrial metabolic disease can explain
better the hallmarks of the disease than can the somatic mutation
theory.
The mechanism by which a broad range of disparate
environmental carcinogens and rare germ line mutations
might produce tumors through a common mechanism was
referred to as the oncogenic paradox (Szent-Gyorgyi, 1977;
Cairns, 1981; Seyfried et al., 2014). We recently explained
the oncogenic paradox by describing how most, if not all,
recognized carcinogens could damage cellular respiration thus
shifting energy production from oxidative phosphorylation to
substrate level phosphorylation (Seyfried and Shelton, 2010;
Seyfried, 2012a; Seyfried et al., 2014). This would also include
alterations in the tissue morphogenetic fields. A protracted shift
from respiration to fermentation will acidify and destabilize
the tissue microenvironment, and thus the morphogenetic field
(Sonnenschein and Soto, 1999; Fosslien, 2008; Bissell and Hines,
2011). Microenvironment acidification enhances angiogenesis
and facilitates the path to tumorigenesis (Sonnenschein and
Soto, 1999; Gatenby and Gillies, 2004; Soto and Sonnenschein,
2004). This is consistent with view of the tumor as an unhealed
wound (Dvorak, 1986). While many genetic abnormalities
will arise through epigenetic phenomena, once established,
genome instability could contribute to further respiratory
impairment, genome mutability, and tumor progression (Rubin,
1985; Seyfried, 2001; Seyfried and Shelton, 2010). At some
point, the nuclear genomic instability in the tumor cells would
prevent a return to normal cellular homeostasis. What develops
then is an escalating situation of biological chaos, where the
intrinsic properties of the immune system (macrophages and
local stroma) to heal wounds would enhance proliferation in
tissue stem cells and their progenitors (Seyfried, 2001). Genomic
instability and transformation accompany the biological chaos.
Collectively, these powerful intrinsic properties drive each other
to greater levels of biological disorder and unpredictability
all of which arise initially from chronic injury to cellular
respiration.
Conclusion
In summary, the information presented here supports the notion
that cancer originates from damage to the mitochondria in
the cytoplasm rather than from damage to the genome in the
nucleus. The genomic damage in tumor cells follows, rather than
precedes, the disturbances in cellular respiration. This view is
also consistent with the previous findings of Roskelley et al.
(1943), Hu et al. (2012). It is unclear how many researchers
in the cancer field are aware of the evidence supporting the
mitochondrial origin of the disease. Payton Rous stated that;
“the somatic mutation theory acts like a tranquilizer on those
who believe in it” (Rous, 1959). Rous’ statement was prophetic
in light of the present embrace of the somatic mutation theory,
despite the glaring inconsistencies with this theory. I attribute
the slow progress in the “War on Cancer” to the persistent
embrace of the somatic mutation theory, and to the failure in
recognizing mitochondrial dysfunction as a credible alternative
explanation for the origin of the disease (Seyfried, 2012a). We
recently described how the somatic mutations in tumors cells
would reduce adaptability to stress, thus making the tumor
cells vulnerable to elimination through “press-pulse” metabolic
therapies involving non-toxic drugs and ketogenic diets (Seyfried
and Mukherjee, 2005; Seyfried et al., 2014). It is my opinion that
real progress in cancer management and prevention will emerge
once the cancer field abandons the somatic mutation theory and
comes to recognize the role of the mitochondria in the origin,
management, and prevention of the disease.
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